Home Cart Sign in  
Chemical Structure| 4865-84-3 Chemical Structure| 4865-84-3

Structure of 4865-84-3

Chemical Structure| 4865-84-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 4865-84-3 ]

CAS No. :4865-84-3
Formula : C9H7NO3
M.W : 177.16
SMILES Code : O=C(O)CC1=NOC2=C1C=CC=C2
MDL No. :MFCD02180388
InChI Key :BVSIAYQIMUUCRW-UHFFFAOYSA-N
Pubchem ID :301729

Safety of [ 4865-84-3 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313

Computational Chemistry of [ 4865-84-3 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 9
Fraction Csp3 0.11
Num. rotatable bonds 2
Num. H-bond acceptors 4.0
Num. H-bond donors 1.0
Molar Refractivity 45.55
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

63.33 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.31
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.2
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.45
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.77
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.56
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.26

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.07
Solubility 1.49 mg/ml ; 0.00842 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.13
Solubility 1.32 mg/ml ; 0.00748 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.69
Solubility 0.362 mg/ml ; 0.00204 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.53 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.38

Application In Synthesis of [ 4865-84-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 4865-84-3 ]

[ 4865-84-3 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 109-83-1 ]
  • [ 50-00-0 ]
  • [ 4865-84-3 ]
  • [ 66233-65-6 ]
  • 2
  • [ 67-56-1 ]
  • [ 4865-84-3 ]
  • [ 59899-88-6 ]
  • 3
  • [ 50-00-0 ]
  • [ 4865-84-3 ]
  • [ 124-40-3 ]
  • [ 66233-73-6 ]
  • 5
  • [ 50-00-0 ]
  • [ 4865-84-3 ]
  • [ 74-89-5 ]
  • (2-benzo[<i>d</i>]isoxazol-3-yl-allyl)-methyl-amine [ No CAS ]
  • 6
  • [ 4865-84-3 ]
  • [ 74-89-5 ]
  • [ 57148-82-0 ]
  • 7
  • [ 4865-84-3 ]
  • 3-sulfamoylmethyl-benzo[<i>d</i>]isoxazole-5-sulfonic acid amide [ No CAS ]
  • 8
  • [ 4865-84-3 ]
  • [ 50471-23-3 ]
  • 9
  • [ 4865-84-3 ]
  • [ 53530-69-1 ]
  • 10
  • [ 4865-84-3 ]
  • [ 53530-68-0 ]
  • 11
  • [ 4865-84-3 ]
  • [ 69169-02-4 ]
  • 12
  • [ 4865-84-3 ]
  • [ 37924-67-7 ]
YieldReaction ConditionsOperation in experiment
6 g With bromine; acetic acid; at 40℃; for 2h; 1,2-Benzisoxazole-3-acetic acid (compound 3-1) (5 g, 0.028 mol) was added to the reaction flask,Then add acetic acid (20ml), at room temperature, slowly dropping liquid bromine (4. 5g, 0. 028m0l), droppingAfter completion, and then heated to 40 C reaction 2 hours later, TLC detection, raw material reaction completely. The reaction was poured into iceWater, a solid product precipitation, stirring for half an hour, filtration, drying, obtained light yellow solid product (compound3-2, 6g).
  • 13
  • [ 4865-84-3 ]
  • [ 69169-01-3 ]
  • 14
  • [ 4865-84-3 ]
  • [ 57148-90-0 ]
YieldReaction ConditionsOperation in experiment
67.8% To a solution of benzo [d]isoxazol-3-yl-acetic (0.86 g, 4.85 mmol) in anhydrous THF (40 mL) was added dropwise borane dimethylsulfide complex (0.58 mL, 10 M, 5.8 mmol) at 0C. The mixture was allowed to warm to room temperature and was stirred over night. MeOH (10 mL) was carefully added and when the gas evolution ceased, the mixture was heated under gentle reflux for 4 hours. The reaction mixture was concentrated in vacuo and the remainder was dissolved in dichloromethane (20 mL). An aqueous solution of Na2C03 (20 mL) was added and the aqueous layer was extracted with dichloromethane (3 x 20 mL). The combined organic layers were dried over Na(at)S04 and concentrated in vacuo. The crude product was purified by chromatography on silica gel which afforded 537 mg (67.8%) of the title compound. ¹3C NMR (125.7 MHz, CDCl3) 8 163.06,156.92, 130.27,123.65, 121.98, 121.65, 110.10, 60.34, 29.01
67.8% With dimethylsulfide borane complex; In tetrahydrofuran; at 0 - 20℃; for 4h;Heating / reflux; To a solution of (benzo[<]isoxazol-3-yl)acetic acid (0.86 g, 4.85 mmol) in anhydrous THF (40 mL) was added, dropwise at 0C, borane-dimethylsulfide complex (0.58 mL, 10 M, 5.8 mmol). The resulting mixture was allowed to warm to room temperature and was then stirred overnight. MeOH (10 mL) was carefully added and, when gas evolution had ceased, the mixture was heated under <n="101"/>gentle reflux for 4 hours. The reaction mixture was concentrated in vacuo and the resulting residue was dissolved in DCM (20 mL). An aqueous solution of Na2CC>3 (20 mL) was added and the aqueous layer was extracted with DCM (3 x 20 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The crude product was then purified by chromatography on silica gel to provide 537 mg (67.8%) of the title compound.13C NMR (125.7 MHz, CDCl3): delta 163.06, 156.92, 130.27, 123.65, 121.98, 121.65, 110.10, 60.34, 29.01
  • 15
  • [ 4865-84-3 ]
  • [ 69203-02-7 ]
  • 16
  • [ 4865-84-3 ]
  • [ 37924-95-1 ]
  • 18
  • [ 4865-84-3 ]
  • [ 69203-03-8 ]
  • 19
  • [ 4865-84-3 ]
  • [ 53530-70-4 ]
  • 20
  • [ 4825-81-4 ]
  • [ 4865-84-3 ]
  • 21
  • [ 106-52-5 ]
  • [ 4865-84-3 ]
  • [ 738538-21-1 ]
  • 22
  • [ 42248-31-7 ]
  • [ 4865-84-3 ]
  • 3-(2-benzo[<i>d</i>]isoxazol-3-yl-vinyl)-6-chloro-chromen-4-one [ No CAS ]
  • 23
  • [ 42059-81-4 ]
  • [ 4865-84-3 ]
  • 3-(2-benzo[<i>d</i>]isoxazol-3-yl-vinyl)-6-methyl-chromen-4-one [ No CAS ]
  • 24
  • [ 42059-75-6 ]
  • [ 4865-84-3 ]
  • 3-(2-benzo[<i>d</i>]isoxazol-3-yl-vinyl)-6,8-dimethyl-chromen-4-one [ No CAS ]
  • 25
  • [ 40682-97-1 ]
  • [ 4865-84-3 ]
  • 3-(2-benzo[<i>d</i>]isoxazol-3-yl-vinyl)-7-methyl-chromen-4-one [ No CAS ]
  • 26
  • [ 64481-12-5 ]
  • [ 4865-84-3 ]
  • 3-(2-benzo[<i>d</i>]isoxazol-3-yl-vinyl)-6-chloro-7-methyl-chromen-4-one [ No CAS ]
  • 27
  • [ 64481-10-3 ]
  • [ 4865-84-3 ]
  • 3-(2-benzo[<i>d</i>]isoxazol-3-yl-vinyl)-6,8-dichloro-chromen-4-one [ No CAS ]
  • 28
  • [ 4865-84-3 ]
  • 8-Chloro-4-oxo-4H-chromene-3-carbaldehyde [ No CAS ]
  • 3-(2-benzo[<i>d</i>]isoxazol-3-yl-vinyl)-8-chloro-chromen-4-one [ No CAS ]
  • 29
  • [ 4865-84-3 ]
  • [ 69169-03-5 ]
  • 30
  • [ 4865-84-3 ]
  • [ 642087-62-5 ]
  • 31
  • [ 4865-84-3 ]
  • C13H20N3O3P [ No CAS ]
  • 32
  • [ 4865-84-3 ]
  • C13H16Cl3N2O3P [ No CAS ]
  • 33
  • [ 4865-84-3 ]
  • C13H18Cl2N3O3P [ No CAS ]
  • 34
  • [ 4865-84-3 ]
  • C13H15Cl3N3O5P [ No CAS ]
  • 35
  • [ 4865-84-3 ]
  • C13H17Cl2N4O5P [ No CAS ]
 

Historical Records

Technical Information

Categories